Atacand Superiority Claim Versus Cozaar Clears FDA With Dosing Caveat
Executive Summary
AstraZeneca Atacand antihypertensive superiority labeling claim over Merck's Cozaar includes the caveat that the drug's efficacy over twice-daily Cozaar has not yet been studied